Literature DB >> 27644320

Prostate cancer: Moderate hypofractionated radiotherapy - not yet a standard of care.

Alan Pollack1, Matthew Abramowitz1.   

Abstract

Entities:  

Mesh：

Year:  2016        PMID： 27644320     DOI： 10.1038/nrclinonc.2016.147

Source DB:  PubMed          Journal:  Nat Rev Clin Oncol        ISSN： 1759-4774            Impact factor:   66.675


× No keyword cloud information.
  10 in total

1.  Updated results and patterns of failure in a randomized hypofractionation trial for high-risk prostate cancer.

Authors:  Stefano Arcangeli; Lidia Strigari; Sara Gomellini; Biancamaria Saracino; Maria Grazia Petrongari; Paola Pinnarò; Valentina Pinzi; Giorgio Arcangeli
Journal:  Int J Radiat Oncol Biol Phys       Date:  2012-04-24       Impact factor: 7.038

2.  A prospective phase III randomized trial of hypofractionation versus conventional fractionation in patients with high-risk prostate cancer.

Authors:  Giorgio Arcangeli; Biancamaria Saracino; Sara Gomellini; Maria Grazia Petrongari; Stefano Arcangeli; Steno Sentinelli; Simona Marzi; Valeria Landoni; Jack Fowler; Lidia Strigari
Journal:  Int J Radiat Oncol Biol Phys       Date:  2010-01-04       Impact factor: 7.038

3.  Randomized trial comparing two fractionation schedules for patients with localized prostate cancer.

Authors:  Himu Lukka; Charles Hayter; Jim A Julian; Padraig Warde; W James Morris; Mary Gospodarowicz; Mark Levine; Jinka Sathya; Richard Choo; Hugh Prichard; Michael Brundage; Winkle Kwan
Journal:  J Clin Oncol       Date:  2005-09-01       Impact factor: 44.544

4.  Hypofractionated versus conventionally fractionated radiation therapy for prostate carcinoma: updated results of a phase III randomized trial.

Authors:  Eric E Yeoh; Richard H Holloway; Robert J Fraser; Rochelle J Botten; Addolorata C Di Matteo; Julie Butters; Sujeeva Weerasinghe; Prasad Abeysinghe
Journal:  Int J Radiat Oncol Biol Phys       Date:  2006-09-11       Impact factor: 7.038

5.  Hypofractionated versus conventionally fractionated radiotherapy for patients with prostate cancer (HYPRO): late toxicity results from a randomised, non-inferiority, phase 3 trial.

Authors:  Shafak Aluwini; Floris Pos; Erik Schimmel; Stijn Krol; Peter Paul van der Toorn; Hanja de Jager; Wendimagegn Ghidey Alemayehu; Wilma Heemsbergen; Ben Heijmen; Luca Incrocci
Journal:  Lancet Oncol       Date:  2016-03-09       Impact factor: 41.316

6.  Randomized trial of hypofractionated external-beam radiotherapy for prostate cancer.

Authors:  Alan Pollack; Gail Walker; Eric M Horwitz; Robert Price; Steven Feigenberg; Andre A Konski; Radka Stoyanova; Benjamin Movsas; Richard E Greenberg; Robert G Uzzo; Charlie Ma; Mark K Buyyounouski
Journal:  J Clin Oncol       Date:  2013-10-07       Impact factor: 44.544

7.  Hypofractionated versus conventionally fractionated radiotherapy for patients with localised prostate cancer (HYPRO): final efficacy results from a randomised, multicentre, open-label, phase 3 trial.

Authors:  Luca Incrocci; Ruud C Wortel; Wendimagegn Ghidey Alemayehu; Shafak Aluwini; Erik Schimmel; Stijn Krol; Peter-Paul van der Toorn; Hanja de Jager; Wilma Heemsbergen; Ben Heijmen; Floris Pos
Journal:  Lancet Oncol       Date:  2016-06-20       Impact factor: 41.316

8.  Randomized Phase III Noninferiority Study Comparing Two Radiotherapy Fractionation Schedules in Patients With Low-Risk Prostate Cancer.

Authors:  W Robert Lee; James J Dignam; Mahul B Amin; Deborah W Bruner; Daniel Low; Gregory P Swanson; Amit B Shah; David P D'Souza; Jeff M Michalski; Ian S Dayes; Samantha A Seaward; William A Hall; Paul L Nguyen; Thomas M Pisansky; Sergio L Faria; Yuhchyau Chen; Bridget F Koontz; Rebecca Paulus; Howard M Sandler
Journal:  J Clin Oncol       Date:  2016-04-04       Impact factor: 44.544

9.  Risk of late toxicity in men receiving dose-escalated hypofractionated intensity modulated prostate radiation therapy: results from a randomized trial.

Authors:  Karen E Hoffman; K Ranh Voong; Thomas J Pugh; Heath Skinner; Lawrence B Levy; Vinita Takiar; Seungtaek Choi; Weiliang Du; Steven J Frank; Jennifer Johnson; James Kanke; Rajat J Kudchadker; Andrew K Lee; Usama Mahmood; Sean E McGuire; Deborah A Kuban
Journal:  Int J Radiat Oncol Biol Phys       Date:  2014-04-01       Impact factor: 7.038

10.  Conventional versus hypofractionated high-dose intensity-modulated radiotherapy for prostate cancer: 5-year outcomes of the randomised, non-inferiority, phase 3 CHHiP trial.

Authors:  David Dearnaley; Isabel Syndikus; Helen Mossop; Vincent Khoo; Alison Birtle; David Bloomfield; John Graham; Peter Kirkbride; John Logue; Zafar Malik; Julian Money-Kyrle; Joe M O'Sullivan; Miguel Panades; Chris Parker; Helen Patterson; Christopher Scrase; John Staffurth; Andrew Stockdale; Jean Tremlett; Margaret Bidmead; Helen Mayles; Olivia Naismith; Chris South; Annie Gao; Clare Cruickshank; Shama Hassan; Julia Pugh; Clare Griffin; Emma Hall
Journal:  Lancet Oncol       Date:  2016-06-20       Impact factor: 41.316
  10 in total
  1 in total

1.  The 5-year outcomes of moderately hypofractionated radiotherapy (66 Gy in 22 fractions, 3 fractions per week) for localized prostate cancer: a retrospective study.

Authors:  Yaichiro Hashimoto; Atsushi Motegi; Tetsuo Akimoto; Norio Mitsuhashi; Junpei Iizuka; Kazunari Tanabe; Yuka Ishii; Sawa Kono; Sachiko Izumi; Kumiko Karasawa
Journal:  Int J Clin Oncol       Date:  2017-07-31       Impact factor: 3.402
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.